Unlearn is a company focused on AI-powered clinical trials, utilizing digital twins of patients to design more efficient, ethical, and reliable clinical studies. They aim to improve treatment comparisons and personalized treatment plans using AI, with the goal of scaling these solutions to turn most of medicine into a computational science.

Advancing artificial intelligence to eliminate trial and error in medicine.

DCVC

DCVC Bio

Alumni Ventures

Eisai

EPIC Ventures

Mubadala Capital Ventures

Insight Partners

Parkway Venture Capital

Radical Ventures

Wittington Ventures

Unlearn.AI

What's the formula for innovation?

🚀 First adopter ⇒ 👀 first follower ⇒  🔂  industry-wide uptake ⇒ 🗑 old status quo into the dustbin  

https://lnkd.in/gXxKVmp8

New post by CEO Charles Fisher addresses a question we're often asked: "What is the FDA's stance on using AI-generated digital twins of clinical trial participants in clinical trials?"

https://lnkd.in/g4g5ZKTd

US FDA comments on Unlearn’s PROCOVA methodology

🚀 Unlearn’s name is a portmanteau of UNsupervised LEARNing and we are an #AI company, not a biotech company. 

➡️ Learn why we started Unlearn: https://bit.ly/3RG7JV8

We train AI models, called Digital Twin Generators, for specific disease indications. To scale our solutions across medicine, we’re going to create a universal Digital Twin Generator, a single model for all of human health. 🌐

🤔 Curious how? Read about our Top Secret Plan for #AI in #medicine here: https://bit.ly/46T9F0M

🌐 At Unlearn, we're driven by a set of core beliefs that guide our work and shape our vision for the #future of #medicine. These beliefs form the foundation of our commitment to harnessing the power of #AI to revolutionize medicine and transform the lives of millions of people worldwide. 

🚀 Want to know how we’re using AI to reinvent the future of medicine? Read our blog: https://bit.ly/47SYsyz

Most #ClinicalTrial participants have one chance at participating in a trial and receiving an experimental treatment that may help them. When participants are randomized to a placebo group, they unknowingly lose that opportunity. 

At Unlearn, we’ve built a novel type of randomized controlled trial design, TwinRCT, which uses #DigitalTwins of clinical trial participants to allow sponsors to safely improve the #power and #speed of their clinical trials. 🚀

Learn how: https://bit.ly/4aegAEu

Ready to redefine what’s possible? Join us at Unlearn, where we’re not just changing the game, but rewriting the rules. 🚀 

Check out our open roles: https://bit.ly/3RJnE5b

“There’s these new technologies for trial execution, and as a community, we have a responsibility to embrace these opportunities and incorporate them into our work so that we can get to more effective outcomes. The big benefit is that we can maybe do things smaller and more efficiently. And we need that because there’s so much more work to do. The ecosystem at the moment doesn’t sustain the way we’ve been doing it traditionally. And (Unlearn) is at the leading edge of this thinking.” 

- Kasper Roet, CEO of QurAlis, shared his thoughts at #CNSSummit2023 on pharma's responsibility to embrace #AI in clinical development and how our AI-generated trial participants' digital twins are leading the way. 🚀 

Streaming now: https://bit.ly/4adS1rC

🌐 This #CrohnsDiseaseAwareness week, we’re shedding light on how AI can help overcome some of the biggest challenges in Crohn’s Disease (CD) clinical development. CD is a chronic disease causing inflammation and gastrointestinal tract irritation. Although several drug classes have been developed to combat CD, an estimated 30-40% of patients do not respond to existing therapies or experience relapses. And while the number of CD trials has increased, patient recruitment is a major obstacle.

Enter our CD Digital Twin Generator 1.0 into the clinical trial arena. Our CD DTG 1.0 enables clinical trials with fewer patients, accelerating clinical development and helping to bring new treatments to patients sooner: https://bit.ly/3uJemwR

#AI #Innovation #CrohnsDisease

AI:UNLEARN

Unlearn

Analysis Not Available